Barreto-Santamaría Adriana, Rivera Zuly Jenny, García Javier Eduardo, Curtidor Hernando, Patarroyo Manuel Elkin, Patarroyo Manuel Alfonso, Arévalo-Pinzón Gabriela
Receptor-Ligand Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Carrera 50#26-20, Bogotá 111321, Colombia.
Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A.), Calle 222#55-37, Bogotá 111166, Colombia.
Microorganisms. 2020 Jun 8;8(6):867. doi: 10.3390/microorganisms8060867.
Antimicrobial peptides (AMPs) have been recognised as a significant therapeutic option for mitigating resistant microbial infections. It has been found recently that -derived, 20 residue long, peptide 35409 had antibacterial and haemolytic activity, making it an AMP having reduced selectivity, and suggesting that it should be studied more extensively for obtaining new AMPs having activity solely targeting the bacterial membrane. Peptide 35409 was thus used as template for producing short synthetic peptides (<20 residues long) and evaluating their biological activity and relevant physicochemical characteristics for therapeutic use. Four of the sixteen short peptides evaluated here had activity against without any associated haemolytic effects. The 35409-1 derivative (17 residues long) had the best therapeutic characteristics as it had high selectivity for bacterial cells, stability in the presence of human sera, activity against multiresistant clinical isolates and was shorter than the original sequence. It had a powerful membranolytic effect and low potential for inducing resistance in bacteria. This peptide's characteristics highlighted its potential as an alternative for combating infection caused by multiresistant bacteria and/or for designing new AMPs.
抗菌肽(AMPs)已被公认为是减轻耐药微生物感染的一种重要治疗选择。最近发现,源自[具体来源未明确]的、由20个残基组成的肽35409具有抗菌和溶血活性,这使其成为一种选择性降低的抗菌肽,并表明应更广泛地研究它,以获得仅靶向细菌膜具有活性的新型抗菌肽。因此,肽35409被用作模板来生产短合成肽(长度小于20个残基),并评估它们的生物学活性和相关物理化学特性以供治疗使用。在此评估的16个短肽中有4个对[具体细菌未明确]具有活性且无任何相关溶血作用。35409 - 1衍生物(长度为17个残基)具有最佳治疗特性,因为它对细菌细胞具有高选择性,在人血清存在下稳定,对多重耐药临床分离株具有活性,并且比原始序列短。它具有强大的膜溶解作用且诱导细菌耐药的可能性低。该肽的特性突出了其作为对抗多重耐药细菌引起的感染的替代方案和/或设计新型抗菌肽的潜力。